Loading clinical trials...

Foundation Model for Post-MI Cardiovascular Event Alert Using Huawei Watch | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Foundation Model for Post-MI Cardiovascular Event Alert Using Huawei Watch

Effect of Smartwatch Along With Foundation Model for the Monitoring and Management of Acute Myocardial Infarction Patients During Outpatient Cardiac Rehabilitation After Percutaneous Coronary Intervention: Protocol for a Randomised Controlled Multicentre Trial

NCT07395648•Tongji Hospital

View on ClinicalTrials.gov

Summary

The goal of this randomized controlled trial is to evaluate whether a HUAWEI smartwatch integrated with a foundation model can enhance daily monitoring and management of AMI patients during outpatient cardiac rehabilitation after PCI. Can a HUAWEI smartwatch with a foundation model improve daily monitoring/management of post-PCI AMI patients during 3-month outpatient CR, vs routine management or smartwatch without AI? Does the AI-enabled smartwatch (Intervention I) reduce 3-month cardiovascular-related hospital/emergency visits vs the other two groups? Do smartwatches (with/without AI) enhance quality of life and activity function post 3-month CR? Does the AI-enabled smartwatch lower 1-year major adverse cardiovascular events (MACEs) and related hospital/emergency visits vs other groups? How accurate is the AI-enabled smartwatch's alert system (vs hospital diagnostic results) for cardiovascular abnormalities? What is the usability of the AI-enabled smartwatch for patients and doctors? Participants will: Sign informed consent; complete baseline exams (MET, SF-36, 6-minute walk, exercise tolerance test) and questionnaires (demographics, medical history, medications). Receive 3-month outpatient CR. Attend follow-ups; report all adverse events promptly. Intervention I (AI-Enabled Smartwatch) group Wear the smartwatch continuously for 3 months (sleep wear recommended); actively collect ≥30s ECG via the watch's crown. Pause activity if heart rate exceeds anaerobic threshold; adjust exercise intensity if METs mismatch prescription. Contact doctors immediately upon receiving abnormality alerts (e.g., heart failure); follow expert recommendations for further care; complete usability questionnaires. Intervention II (Non-AI Smartwatch) group Wear the smartwatch continuously for 3 months (sleep wear recommended) to track activity/sleep, monitor real-time heart rate/MET. Pause activity if heart rate exceeds anaerobic threshold; adjust exercise intensity if METs mismatch prescription. Control Group Complete routine outpatient CR and follow-ups (no smartwatch use).

Eligibility

Age

18 - 69 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged more than equal to 18 years, less than 69 years.
•2. Discharged within 6 months after PCI for acute myocardial infarction, and haven't received outpatient cardiac rehabilitation;
•3. 40%≤EF≤50% and NT-pro BNP ≤500 pg/mL;
•4. With the history of hypertension;
•5. Voluntarily joined and signed the informed consent.

Exclusion Criteria

•1. With contraindication for rehabilitation activities include: unstable angina, uncontrolled hypertension (systolic blood pressure\>180 mmHg and/or diastolic blood pressure\>110 mmHg in a quiet state), severe symptomatic heart valve stenosis, uncontrolled heart rate increase (\>130 beats/minute), uncontrolled heart failure, third degree atrioventricular block (without pacemaker implantation), active pericarditis or myocarditis, presence of newly formed embolism (pulmonary or systemic circulation), aortic dissection, acute thrombophlebitis, acute systemic disease or fever, other metabolic abnormalities (such as acute thyroiditis, electrolyte imbalance, uncorrected blood glucose abnormalities or insufficient blood volume), and severe psychological disorders;
•2. Patients who have a pre-planned staged revascularization procedure (e.g., planned second coronary intervention) following their initial PCI for AMI.
•3. Tattoos or other substances that affect optical signals on the wrist.
•4. Coronary heart disease patients at high risk.
•5. Pregnant women or women planning to become pregnant within the next year.
•6. Severe arrhythmia, including third degree atrioventricular block, ventricular escape rhythm, severe sinus bradycardia, sick sinus syndrome, supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter.
•7. Physical disability, blindness, and deafness.

Key Dates

Start Date

April 1, 2026

Primary Completion Date

December 31, 2027

Completion Date

June 1, 2028

Last Updated

February 9, 2026

Enrollment

1,050

ESTIMATED participants

Conditions

Coronary Artery DiseaseMyocardial Infarction

Interventions

Smartwatch + AI assisted

DEVICE

Smartwatch only

DEVICE

Conventional care

DEVICE

Contacts

Yucong Zhang, M.D.

CONTACT

86 13627115411 u201110541@hust.edu.cn

Fast Discharge After Acute Myocardial Infarction Discharge MI

NCT06744322

Acute Myocardial Infarction (AMI)

View study

RECRUITINGPHASE2

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

NCT05198791

Myocardial Infarction, AcuteMyocardial Infarction With Nonobstructive Coronary Arteries+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Foundation Model for Post-MI Cardiovascular Event Alert Using Huawei Watch

Inclusion Criteria

Exclusion Criteria

Fast Discharge After Acute Myocardial Infarction Discharge MI

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

SuperSaturated Oxygen Comprehensive Observational Registry